Kairos Pharma has announced a 1-for-7 reverse stock split, a corporate action taken to increase its share price and maintain compliance with NYSE listing requirements, as reported by Morningstar and other outlets.

Kairos Pharma has announced a 1-for-7 reverse stock split, a corporate action taken to increase its share price and maintain compliance with NYSE listing requirements.

Kairos Pharma has signed a binding strategic asset acquisition for exclusive worldwide rights to CL-273 from Orbimed and Torrey Pines Investment-backed Celyn Therapeutics.